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Abstract  
Objectives: In HIV-negative populations light to moderate alcohol consumption is 
associated with a lower cardiovascular morbidity and mortality than alcohol abstention. 
Whether the same holds true for HIV-infected individuals has not been evaluated in 
detail.  
Design: Cohort study 
Methods: Adults on antiretroviral therapy in the Swiss HIV Cohort Study with follow-up 
after August 2005 were included. We categorized alcohol consumption into: abstention, 
low (1-9 g/d), moderate (10-29 g/d in females and 10-39g/d in men) and high alcohol 
intake. Cox proportional hazards models were used to describe the association between 
alcohol consumption and cardiovascular disease free survival (combined endpoint) as 
well as cardiovascular disease events (CADE) and overall survival. Baseline and time-
updated risk factors for CADE were included in the models.  
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Results: Among 9,741 individuals included, there were 788 events of major CADE or 
death during 46,719 years of follow-up, corresponding to an incidence of 1.69 
events/100 person-years. Follow-up according to alcohol consumption level was 51% 
abstention, 20% low, 23% moderate and 6% high intake. As compared to abstention, 
low (hazard ratio 0.79, 95% confidence interval 0.63-0.98) and moderate alcohol intake 
(0.78, 0.64-0.95) were associated with a lower incidence of the combined endpoint. 
There was no significant association between alcohol consumption and CADE. 
Conclusions: Compared to abstention, low and moderate alcohol intake were 
associated with a better CADE-free survival. However, this result was mainly driven by 
mortality and the specific impact of drinking patterns and type of alcoholic beverage on 
this outcome remains to be determined. 
 
Key words: Alcohol consumption; HIV infection; Mortality; Cardiovascular diseases; 
Cohort study  
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Introduction 
In the general population, episodic intake of large amounts of alcohol increases 
mortality[1], whereas low to moderate alcohol consumption is associated with a lower 
cardiovascular morbidity and mortality compared to alcohol abstention[2, 3]. Whether 
the latter association depends on the type of alcoholic beverage, the frequency of intake 
or on associated socio-cultural behaviors remains of debate[2, 4, 5].  
In HIV-infected individuals, excessive alcohol consumption has been associated with 
several negative outcomes, including mortality, increased sexual risk-behavior, lower 
adherence to and higher interruptions of antiretroviral therapy (ART) as well as impaired 
response to ART[6-9]. However, only a few studies have assessed the impact of alcohol 
consumption on cardiovascular outcomes in this population. Low or moderate alcohol 
consumption was associated with a low prevalence of cardiovascular disease in an 
American cross-sectional study[10] and a reduced risk of major cardiovascular disease 
events (CADE) in a prospective multisite French cohort[11]. While the first study did not 
differentiate between no alcohol intake and low or moderate consumption, the second 
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was limited by a small sample size and a low number of observed cardiovascular 
events. Importantly, neither study assessed the impact of low and moderate alcohol 
consumption on CADE-free survival and overall mortality. 
We performed a thorough analysis of the association between different levels of alcohol 
consumption and CADE-free survival as well as overall mortality in a large, nationwide 
HIV cohort. In order to reduce confounding, time-updated data on the quantity and 
patterns of alcohol consumption as well as detailed information on all important 
cardiovascular risk factors and HIV-related clinical parameters were adjusted for. 
Methods 
The Swiss HIV Cohort Study 
The Swiss HIV Cohort Study (SHCS, www.shcs.ch) is a prospective cohort study with 
on-going enrolment of HIV-infected adults in Switzerland since 1988. It covers close to 
50% of the cumulative number of HIV infections declared to the Swiss public health 
authorities, and 75% of individuals receiving ART in Switzerland[12]. 
Representativeness remained stable over the years. Detailed information on 
demographics, mode of HIV acquisition, risk behavior, clinical events, co-infections, 
comorbidities and treatment is collected using a standard protocol at registration and 
then at intervals of 6 months. Local ethical committees of all participating study sites 
have approved the study and written consent has been obtained from all participants. 
 
Inclusion criteria and definitions  
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We included all adult individuals enrolled in the SHCS who started ART and had at least 
one follow-up visit with available information on alcohol consumption. We considered 
individual follow-up starting at the first visit with available alcohol data. The alcohol 
questionnaire was introduced into the SHCS routine questionnaire in August 2005. 
Since then, data on self-reported alcohol consumption was collected at 6 months 
intervals for every patient. The questionnaire captures information on the frequency, 
quantity and pattern of alcohol consumption. For this analysis, self-reported alcohol 
consumption was categorized into: abstention or very low (<1g/d), low (1-9 g/d), 
moderate (10-29 g/d in women and 10-39g/d in men) and high alcohol intake (>39g/d). 
 
Outcomes 
Our primary outcome was a combined endpoint of either death or CADE (CADE-free 
survival), whichever occurred first. CADE included myocardial infarction, coronary 
angioplasty, coronary artery bypass grafting, carotid endarterectomy, procedures on 
other arteries, cerebral infarction and cerebral haemorrhage. In the SHCS, data on all 
cardiovascular events are collected on specific, standardized, case-report forms, using 
reports from medical hospitalizations and performed surgery to inform and validate the 
diagnosis.  
The secondary endpoints were the separate outcomes: CADE, overall survival and 
cardiovascular death. 
 
Statistical analyses 
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Baseline characteristics of patients at study inclusion were compared between baseline 
alcohol consumption levels using Kruskal-Wallis and χ2 tests for continuous and 
categorical variables, respectively. The distribution of clinical outcomes across 
categories of alcohol intake was presented as absolute numbers and proportions. 
Cox proportional hazards models were used to evaluate the association between time-
updated alcohol consumption level and CADE-free survival (combined endpoint) as well 
as CADE and overall survival. Follow-up was censored at the time of first major CADE, 
death, or last recorded visit, whichever occurred first. These models were adjusted for 
all relevant baseline demographic and clinical characteristics, including sex, ethnicity 
(black vs. others), education level (low [no or basic education], intermediate [high-
school] and high [high-level education]), HIV transmission group (heterosexual, men 
who have sex with men [MSM], injection drug users [IDU] and others), hepatitis C 
infection (HCV, presence of positive HCV RNA), hepatitis B infection (HBV, positive 
HBs Antigen), CDC stage of infection and family history of cardiovascular disease 
(yes/no). Anemia, an important predictor of mortality among HIV-infected patients[13], 
was included as a binary, time-updated variable (yes/no, cut-off value for women 12 
g/dL and for men 14 g/dL) as the prevalence of severe anemia was inferior to 1% in our 
cohort. Age, body mass index (BMI, normal, underweight or overweight/obese), 
smoking (packs per day), random cholesterol levels (total cholesterol/HDL-cholesterol 
ratio), diabetes mellitus (yes/no), arterial hypertension (yes if systolic blood pressure 
exceeds 140 mmHg or diastolic blood pressure exceeds 90 mmHg, no otherwise), CD4 
cell count, log HIV viral load, as well as ART regimens (cumulative exposure to abacavir 
(ABC), efavirenz (EFV), nevirapine (NVP) and protease inhibitors (PI)) were included as 
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time-varying covariates. We carried forward the last observed value of time-dependent 
covariates. To describe the overall cardiovascular risk profile of the different comparison 
groups, we used the Framingham 10-year cardiovascular disease risk score as a 
summary measure[14]. The association between alcohol consumption and CADE-free 
survival was shown in figures including alcohol as a continuous and categorical 
variable. Similar figures were reproduced for the associations between alcohol intake 
and the secondary outcomes.  
 
Sensitivity analyses  
Education level is associated with health seeking behavior and could condition drinking 
patterns. Thus, in order to assess the possible link between education level and CADE 
free survival, we repeated our analyses after stratification by education level categories 
and a formal test of interaction was performed. Furthermore, to evaluate the impact of 
the definition of our main independent variable, self-reported alcohol consumption, on 
the primary outcome, we compared the results of the main analysis with those of a 
sensitivity analysis in which current alcohol intake was replaced by time-updated 
average consumption since the beginning of the follow-up period. Finally, “sick quitters” 
could have been included into the “no/very low alcohol consumption group” and 
influenced our results. Thus, we repeated the main analyses after excluding the patients 
with an AST-to-Platelet Ratio Index (APRI) score corresponding to liver cirrhosis 
(APRI>2.0) from this alcohol use category. 
All statistical analyses were performed using R version 2.15.2. 
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Results 
Baseline Characteristics 
Of 9,764 patients included in the study, 51% reported no or very low alcohol 
consumption at baseline, while 20%, 22% and 7% had a low, moderate and high 
alcohol intake, respectively (Table 1). Individuals with no or very low alcohol intake were 
more likely to be female and of black ethnicity. The groups with low or moderate alcohol 
consumption at baseline had the lowest proportions of IDU and the highest proportion of 
highly educated patients. Cardiovascular disease risk profile differed between groups. 
Framingham cardiovascular disease 10-year risk score increased with alcohol intake at 
baseline, reaching 7.3% in the group with high alcohol consumption. Whereas smoking 
and arterial hypertension were most prevalent in this group, participants with no or very 
low alcohol intake were most likely to have diabetes mellitus and anemia. 
Individual drinking habits remained fairly constant over time: 53% of patients spent at 
least 80% of their follow-up time in the same drinking category and 92% spent at least 
50% of their time in one category. The incidence rate of change of alcohol consumption 
category was 0.44 per person-year of follow-up. 
 
Distribution of CADE and death according to alcohol intake 
During 46,719 patient-years of follow-up, 788 individuals either developed a CADE or 
died; there were 343 CADE and 491 deaths (Table 2).  Heart CADE, including 
myocardial infarction, coronary angioplasty and coronary artery bypass graft was 
observed in 199 patients (58% of all CADE). The combined outcome was observed in 
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442 (8.8%) patients with no or very low alcohol consumption at baseline, whereas 118 
(6.1%), 155 (7.1%) and 73 (11.4%) patients with low, moderate and high alcohol intake 
developed a CADE or died, respectively. In total, 12.6% of all deaths (62/491) were due 
to cardiovascular events.  
 
Incidence of CADE or death 
The incidence of CADE or death (whichever occurred first) was 1.69 events/100 person-
years (py) (95% confidence interval (CI) 1.57-1.81). Overall follow-up time was 
distributed as follows according to time-updated alcohol consumption: no or very low: 
50.6%, low: 20.4%, moderate: 23.3% and high: 5.7%. Compared to no or very low 
alcohol intake, low (hazard ratio (HR) 0.79, 95% CI 0.63-0.98) and moderate alcohol 
intake (0.78, 0.64-0.95) were associated with a lower incidence of the combined 
endpoint, whereas no association was detected for high intake (1.02, 0.78-1.34) (Table 
3). Figure 1 shows a fitted curve of the association between daily alcohol consumption 
category or continuous level with the HR of the combined endpoint. The classical 
cardiovascular risk factors, including age, diabetes mellitus, smoking, total 
cholesterol/HDL-cholesterol ratio and arterial hypertension, as well as low CD4 cell 
count and anemia were significantly associated with a higher hazard of CADE or death. 
A strong association between education level and the combined outcome was also 
observed (high vs. low: HR 0.73, 95% CI 0.59-0.95). Finally, a significant association 
between cumulative treatment with ABC and PIs and CADE or death could also be 
shown. 
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Secondary outcomes 
The level of alcohol intake predicted overall survival. We observed 491 deaths during 
48,000 py of follow-up, which corresponds to an incidence of 1.03/100py (95% CI: 0.94-
1.12). A J-curve similar to the one for the combined outcome could be shown (Figure 2). 
Compared to very low alcohol consumption, low (HR 0.57, 95% CI 0.42-0.78) and 
moderate alcohol intake (0.60, 0.46-0.80) were associated with a lower incidence of 
death. Again, there was no association between high alcohol intake and death (HR 
1.02, 0.74-1.42). Education level and all classical cardiovascular risk factors were 
associated with mortality, whereas no specific antiretroviral drug was associated with 
this outcome. During 47,000 py of follow-up, 343 CADE events were noted, which 
corresponded to an incidence of 0.73/100py (95% CI: 0.66-0.82). However, low (HR 
1.09, 95% CI 0.81-1.47) or moderate (1.02, 0.77-1.35) alcohol consumption were not 
associated with a lower hazard of CADE, as shown in Figure 2. Similarly, low (HR 1.05, 
95% CI 0.50-2.22) or moderate (HR 1.03, 95% CI 0.51-2.05) alcohol consumption did 
not seem to be associated with lower hazard for cardiovascular death. 
 
Sensitivity analyses 
In stratified analyses, the J-shaped curve of the association between low/moderate 
alcohol intake and the combined outcome remained statistically significant for the 
groups of participants with low or intermediate education levels (see Figure S1, 
Supplemental Digital Content, http://links.lww.com/QAI/A757). This was not the case for 
high education level, but the number of patients in this category reporting high alcohol 
consumption was low. There was no evidence of an interaction between alcohol 
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consumption and education levels in their association with CADE or death (p=0.64). 
Replacing time-updated alcohol consumption by average intake as the main 
independent variable did not change the association between low/moderate alcohol 
intake and the combined outcome (see Figure S2, Supplemental Digital Content, 
http://links.lww.com/QAI/A757). Finally, the results of the main analyses obtained after 
the exclusion of potential “sick quitters” did not vary significantly from the original results 
(data not shown). 
 
Discussion 
Compared to abstention or very low consumption, low and moderate alcohol intake 
were associated with a better CADE-free survival and overall survival in participants of 
the SHCS receiving ART. These observations persisted after adjustment for a wide 
range of classical baseline and time-updated cardiovascular risk factors as well as other 
known predictors of mortality such as CD4 cell count and anemia. However, the 
incidence of CADE seemed to be lower with increasing alcohol consumption, possibly 
due to competing risks. The J-shaped association between alcohol consumption and 
mortality shown previously in the general population also seems to hold true in HIV-
infected individuals on ART. 
Of nearly 10,000 individuals included in this study, 51% were alcohol abstainers or had 
very low consumption at enrollment. Similar proportions have been shown in several 
studies reporting on the proportion of alcohol abstainers in HIV-infected individuals[15, 
AC
CE
PT
ED
Copyright © 201 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.5
13 
 
16]. However, in two recent publications on the association between alcohol 
consumption and cardiovascular events in HIV-infected individuals American veterans 
and French patients had much lower proportions of abstainers[10, 11]. Estimates on low 
or moderate alcohol consumption, the categories of primary interest in this study, are 
not consistently reported across publications. In our study, approximately 42% of 
patients were classified into these categories at baseline, and the proportion of 
participants who remained in these groups over time was fairly constant. In comparison, 
previous landmark studies on the association between moderate alcohol consumption 
and decreased risk of cardiovascular events in HIV-infected and uninfected individuals 
had much higher proportions of individuals with moderate alcohol intake[2, 11]. This is 
of importance as drinking patterns often carry socio-cultural and behavioral 
characteristics along, which vary widely across settings and are themselves linked to 
comorbidities and health seeking behavior[17].  
We found a moderate association between low or moderate alcohol consumption and 
CADE-free as well as overall survival, after adjustment for all relevant cardiovascular 
risk factors and parameters of advanced HIV disease. The impact of alcohol intake on 
these outcomes was consistent across strata of education level and did not change 
significantly whether alcohol was considered as a time-varying covariate or an average 
estimate. Furthermore, these J-shaped associations could be shown in analyses 
including alcohol intake as a categorical or continuous variable and the magnitude was 
similar to published analyses from studies in HIV-uninfected patients[18, 19]. These 
findings confirm the results of larger studies in the general population, where a causal 
link between moderate alcohol consumption and mortality has become evident, 
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including the biological plausibility[3, 20]. Although HDL-cholesterol levels increased 
with higher alcohol intake in our study, there was no difference between abstainers and 
patients with low alcohol intake. Thus, the potential protective effect of HDL-cholesterol 
linked to the consumption of red wine could not be shown.  
In contrast to the study by Carrieri et al[11], we did not find a significant association 
between alcohol intake and CADE, despite having a much larger sample size and a 7-
fold higher number of major CADE, resulting in very similar overall incidence estimates 
(0.73 (0.66-0.82) per 100 patient-years in our study vs. 0.75 (0.57-0.99) in Carrieri et 
al.[11]). There are several potential explanations for these divergent results: First, there 
was a large group of patients with very low consumption in the study by Carrieri et al. 
and only few abstainers. Unfortunately, in our study, we were not able to distinguish 
abstainers from patients with very low alcohol consumption (less than 1 drink per 
week).. Thus, the category “no or very low alcohol consumption” could have included 
patients with good cardiovascular profile (as shown by the low Framingham 
cardiovascular risk score in this group) and a smaller group of less healthy individuals 
(for example “sick quitters”). However, in a sensitivity analyses performed after the 
exclusion of abstainers with possible liver cirrhosis, we did not find significant 
differences in the association between alcohol consumption and the main outcomes. 
Second, we may have over-corrected our model by including clinical and laboratory 
CADE risk factors which may have been on the causal pathway between alcohol 
consumption and protection of CADE. However, a forward step-wise adjustment 
strategy did not confirm this potential explanation. Finally, the difference in the results 
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between the two studies might have occurred due to the use of time-updated covariates 
in our analyses.  
All main cardiovascular risk factors, including age, smoking, arterial hypertension, 
diabetes mellitus and hyperlipidemia, as well as anemia, were associated with the 
hazard of CADE, CADE-free survival and death. This strengthens the validity of our 
model and shows the need to rely on high quality data on these confounders when 
analyzing the impact of alcohol on long-term clinical outcomes. The impact of several 
antiretroviral drugs on cardiovascular events has been much debated in recent years. 
Abacavir (ABC) has been in the forefront of these discussions, as several large scale 
observational studies had shown its potential impact on myocardial infarction[21, 22]. In 
our study, time spent on ABC was a significant risk factor of CADE and CADE-free 
survival but not of overall survival. However, the point estimates were close to 1 and we 
did not adjust our analyses for renal dysfunction, which has been shown to be a 
potential confounder in such analyses[22].  
This is the first study to assess the impact of different alcohol consumption levels on 
cardiovascular disease free survival in a nationwide population of HIV-infected 
individuals. Taking advantage of the systematic and repeated collection of detailed 
information on alcohol consumption within the framework of the SHCS, we were able to 
determine each patient’s intake over time and to classify all individuals into one of the 
main alcohol consumption categories. Furthermore, dedicated ascertainment of 
cardiovascular events and reasons of death, as well as the availability of information on 
all classical cardiovascular risk factors over time allowed us to study the impact of 
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baseline and time-updated alcohol intake on several long-term outcomes in detail. The 
main limitations of our study are the self-reported nature of individual alcohol 
consumption, which might have led to some degree of reporting bias, and the lack of 
information on the type of alcoholic beverage consumed. Thus, we were not able to 
disentangle the relationship between specific types of alcohol, for example wine in the 
“French paradox”, and long-term outcomes. However, it has been suggested that the 
type of alcohol might not play such an important role as the beverage most widely 
consumed seems to be the one most likely to have a protective effect on the risk of 
cardiovascular events and death[5]. 
Our study underlines the protective effect of low and moderate alcohol consumption on 
cardiovascular event free survival and overall survival. Thus, there is no signal that low 
to moderate alcohol consumption should be avoided by HIV-infected persons on ART. 
However, the main reasons for this association are still unclear. In this regard, the role 
played by different types of alcoholic beverages, drinking patterns as well as social and 
behavioral characteristics linked to them need to be further explored. Furthermore, 
these findings warrant more detailed analyses of causes of death besides 
cardiovascular events in order to inform public health strategies and guidance on the 
benefits and risks of low and moderate alcohol consumption.  
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Figure 1: Impact of daily alcohol consumption category (Panel A) and continuous 
level (Panel B) on the combined endpoint (CADE or death) 
Figure 2: Impact of daily alcohol consumption category and continuous level on 
separate endpoints (A and B: death, C and D: CADE)  
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Table 1. Baseline characteristics of study population, by level of alcohol intake  
  No or very 
low 
N=5006  
Low 
N=1950  
Moderate                  
N=2170  
High                 
N= 638 
p-value 
Female sex (%) 1970 (39.4) 442 (22.7) 343 (15.8) 135 (21.2) <0.001 
Median age in years (IQR) 41 (34-47) 41 (36-48) 43 (37-49) 44 (39-50) <0.001 
Black ethnicity (%) 956 (19.1) 178 (9.1) 183 (8.4) 32 (5.0) <0.001 
HIV transmission group (%)         <0.001 
    Heterosexual 2232 (46.6) 628 (32.2) 686 (31.6) 233 (36.5)  
    IDU 911 (18.2) 195 (10.0) 288 (13.3) 180 (28.2)  
    MSM 1589 (31.7) 1053 (54.0) 1116 (51.4) 209 (32.8)  
    Other 274 (5.5) 74 (3.8) 80 (3.7) 16 (2.5)  
Education level (%)     <0.001 
    No  1524 (31.7) 329 (17.4) 427 (20.2) 176 (29.1)  
    Basic  2278 (47.4) 1029 (54.3) 1032 (48.9) 312 (51.7)  
    High-level 1003 (20.9) 537 (28.3) 651 (30.9) 116 (19.2)  
Median CD4 count (IQR) 379 (247-570) 380 (260-560) 392 (264-85) 360 (231-550) 0.01 
Median log HIV RNA (IQR) 0 (0-4) 1.7 (0-4.5) 1.5 (0-4.5) 1.9 (0-4.4) <0.001 
HCV infection (%) 253 (5.1) 84 (4.3) 74 (3.4) 35 (5.5) 0.01 
HBV infection (%) 261 (5.2) 72 (3.7) 105 (4.8) 33 (5.2) 0.06 
CDC stage C (%) 1277 (25.5) 384 (19.7) 455 (21.0) 148 (23.2) <0.001 
PI-based ART (%) 2559 (51.1) 1020 (52.3) 948 (43.7) 288 (45.1) <0.001 
ART including ABC (%) 949 (19.0) 352 (18.1) 439 (20.2) 101 (15.8) 0.06 
Family history (%) 513 (10.5) 215 (11.3) 271 (12.7) 69 (11.1) 0.07 
total cholesterol/HDL-C 
ratio 
4,0 (3.2-5.1) 4,0 (3.1-5.0) 4,0 (3.2-5.0) 3,6 (2.8-4.5) <0.001 
Median HDL-cholesterol in 
mmol/L (IQR) 
1,1 (0.9-1.4) 1,1 (0.9-1.4) 1,2 (0.9-1.5) 1,3 (1.0-1.7) <0.001 
Diabetes (%) 185 (3.7) 58 (3.0) 44 (2.0) 13 (2.0) 0.001 
BMI (%)     <0.001 
    Normal 2997 (62.3) 1225 (64.3) 1383 (66.3) 425 (68.4)  
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    Underweight  389 (8.1) 105 (5.5) 100 (4.8) 44 (7.1)  
    Overweight/obese  1423 (29.6) 575 (30.2) 604 (28.9) 152 (24.5)  
Arterial hypertension (%) 766 (15.4) 381 (19.6) 398 (18.5) 170 (26.6) <0.001 
Median pack/d smoking 
(IQR) 
0 (0-0.8) 0 (0-0.8) 0 (0-1) 1,0 (0-1.2) <0.001 
Anemia (%) 1863 (37.2) 599 (30.7) 664 (30.6) 208 (32.6) <0.001 
Median Framingham score 
(IQR) 
4.5 (2.0-9.4) 5.2 (2.6-10.2) 6.5 (3.3-11.9) 7.3 (3.9-12.8) <0.001 
IDU: injection drug users; MSM: men who have sex with men; HBV: hepatitis B virus; HCV: 
hepatitis C virus; CDC: center for diseases control; PI: protease inhibitor; ART antiretroviral 
therapy; ABC: abacavir; BMI: body mass index; IQR: interquartile range; BMI: body mass index 
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Table 2. Distribution of outcomes, by level of alcohol intake 
 No or 
very low 
Low Moderate High 
Number of patients  5006 1950 2170 638 
Myocardial infarction (%) 53 (1.1) 29 (1.5) 37 (1.7) 7 (1.1) 
Coronary angioplasty (%) 29 (0.6) 11 (0.6) 18 (0.8) 4 (0.6) 
Coronary artery bypass graft (%) 6 (0.1) 3 (0.2) 1 (0.1) 1 (0.2) 
Carotid endarterectomy (%) 2 (0.04) 1 (0.1) 0 1 (0.2) 
Procedures on other arteries (%) 28 (0.6) 7 (0.4) 11 (0.5) 2 (0.3) 
Cerebral infarction (%) 39 (0.8) 16 (0.8) 17 (0.8) 6 (0.9) 
Cerebral hemorrhage (%) 4 (0.1) 2 (0.1) 6 (0.3) 2 (0.3) 
Deaths (%) 313 (6.3) 53 (2.7) 71 (3.3) 54 (8.4) 
CV deaths 27 (0.5) 10 (0.5) 14 (0.6) 11 (1.7) 
Combined outcomes 
    
CADE (%) 161 (3.2) 68 (3.5) 90 (4.1) 23 (3.6) 
Heart CADE (%) 88 (1.8) 43 (2.2) 56 (2.6) 12 (1.9) 
CADE or death (%) 442 (8.8) 118 (6.1) 155 (7.1) 73 (11.4) 
CADE or CV death (%) 178 (3.6) 76 (3.9) 102 (4.7) 31 (4.9) 
CADE: cardiovascular disease events; CV cardiovascular 
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Table 3. Predictors of CADE or death 
 Univariable analysis  Multivariable analysis 
 HR (95% CI) p-value  HR (95% CI) p-value 
Alcohol intake 
 <0.001   0.03 
    No or very low Ref.   Ref.  
    Low 0.66 (0.54-0.81)   0.79 (0.63-0.98)  
    Moderate 0.76 (0.64-0.92)   0.78 (0.64-0.95)  
    High 1.45 (1.13-1.86)   1.02 (0.78-1.34)  
Sex 
 <0.001   0.39 
    Male Ref.   Ref.  
    Female 0.62 (0.53-0.74)   0.91 (0.74-1.12)  
Median age in years  
 <0.001   <0.001 
    Per 1 year increase 1.06 (1.06-1.07)   1.06 (1.05-1.07)  
Education level  
 0.10   0.03 
    No/basic Ref.   Ref.  
    High school  0.97 (0.82-1.15)   0.82 (0.68-0.98)  
    High-level 0.81 (0.65-1.00)   0.75 (0.59-0.95)  
Transmission group 
 <0.001   <0.001 
    HET Ref.   Ref.  
    IDU 2.27 (1.91-2.70)   1.71 (1.37-2.12)  
    MSM 1.09 (0.92-1.29)   1.00 (0.82-1.22)  
Ethnicity 
 <0.001   0.01 
    Non-black Ref.   Ref.  
    Black 0.27 (0.19-0.38)   0.55 (0.37-0.83)  
Anemia 
 <0.001   <0.001 
    No Ref.   Ref.  
    Yes 3.51 (3.05-4.04)   2.36 (2.02-2.77)  
Log CD4 count  
 <0.001   <0.001 
    Per 1 log increase 0.15 (0.13-0.18)   0.26 (0.21-0.32)  
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CDC stage C 
 <0.001   0.01 
    No Ref.   Ref.  
    Yes 2.02 (1.75-2.32)   1.22 (1.04-1.43)  
Log HIV RNA  
 <0.001   0.08 
    Per 1 log increase 1.17 (1.12-1.23)   1.05 (0.99-1.11)  
HBV exposure 
 0.19   0.17 
    No Ref.   Ref.  
    Yes 1.22 (0.91-1.65)   1.25 (0.91-1.72)  
HCV infection 
 0.03   0.13 
    No Ref.   Ref.  
    Yes 1.38 (1.04-1.83)   0.78 (0.56-1.08)  
Cumulative ABC exposure  
 <0.001   <0.001 
    Per unit increase 1.09 (1.06-1.11)   1.08 (1.05-1.10)  
Cumulative EFV exposure 
 0.38   0.53 
    Per unit increase 1.01 (0.99-1.04)   1.01 (0.98-1.04)  
Cumulative NVP exposure 
 0.90   0.96 
    Per unit increase 1.00 (0.97-1.04)   1.00 (0.96-1.04)  
Cumulative PI exposure 
 <0.001   0.09 
    Per unit increase 1.08 (1.06-1.09)   1.02 (1.00-1.04)  
Family history  
 0.02   0.21 
    No  Ref.   Ref.  
    Yes 1.27 (1.03-1.55)   1.15 (0.93-1.43)  
BMI  
 <0.001   <0.001 
    Normal Ref.   Ref.  
    Underweight  2.78 (2.28-3.39)   1.58 (1.26-1.97)  
    Overweight/obese  0.84 (071-0.98)   0.85 (0.71-1.01)  
Diabetes 
 <0.001   <0.001 
    No Ref.   Ref.  
    Yes 3.15 (2.55-3.91)   1.89 (1.49-2.40)  
Arterial hypertension  
 <0.001   0.001 
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Figure 1: Impact of daily alcohol consumption category (Panel A) and continuous 
level (Panel B) on the combined endpoint (CADE or death) 
 
A                                                                           B 
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Figure 2: Impact of daily alcohol consumption category and continuous level on 
separate endpoints (A and B: death, C and D: CADE)  
A              B                        
 
C              D 
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